TacticScaleWhat Pfizer Does & How It Makes Money (PFE)
Updated October 2026 · reflects Pfizer's latest reported financials
Global drugmaker selling medicines and vaccines across major disease areas. Pfizer makes money by selling branded prescription drugs, vaccines, biosimilars, and sterile injectables to healthcare systems in the US and abroad.
How Pfizer makes money
Pfizer makes money by selling branded prescription drugs, vaccines, biosimilars, and sterile injectables to healthcare systems in the US and abroad. Some products are developed or sold together with partners such as Bristol-Myers Squibb, Astellas, and BioNTech.
What Pfizer does
Pfizer Inc., founded in 1849 and headquartered in New York, is one of the largest biopharmaceutical companies in the world. It reports three segments: Biopharma, PC1, and Pfizer Ignite. Its internal medicine business includes the blood thinner Eliquis, the migraine drugs Nurtec ODT and Zavzpret, the Prevnar and Abrysvo vaccines, and the COVID-19 treatment Paxlovid. It also sells immunology drugs such as Xeljanz and Enbrel, and rare-disease treatments such as the Vyndaqel family for amyloidosis. Oncology is a major area. Pfizer sells antibody-drug conjugates (ADCs), small molecules, and bispecific antibodies, including Ibrance, Xtandi, Padcev, Adcetris, Lorbrena, and Elrexfio. It also sells biosimilars and hospital sterile injectables. Pfizer works with partners including Bristol-Myers Squibb, Astellas, Merck KGaA, and BioNTech. It also has a collaboration with Boltz to develop AI models for biomolecules.
Products & services
- Eliquis
- Prevnar
- Paxlovid
- Vyndaqel
- Ibrance
- Xtandi
What is Pfizer worth?
On an owner-earnings DCF, Pfizer's most-likely value is about $29 versus a recent price near $28 (3% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$20) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Bristol-Myers Squibb (BMY) · Merck (MRK) · Viatris (VTRS) · Eli Lilly and (LLY) · Jiangsu Hengrui Pharmaceuticals (600276.SS)